The Medtronic commitment to quality has long been stated in our Mission, “To strive without reserve for the greatest possible reliability and quality in our products; to be the unsurpassed standard of comparison and to be recognized as a company of dedication, honesty, integrity, and service.”
In line with this commitment we remain focused on sharing information and appropriate updates with customers on a regular basis. Thus, we are pleased to share the 12th Annual Medtronic Neuromodulation Product Performance Report.
We are proud of our pioneering history at Medtronic and we realize the responsibility that comes with driving innovation in technology. As the first and only company to offer a full line of Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Neuromodulation and Targeted Drug Delivery therapies, we believe that performance reporting is of critical importance as we strive for better performance with every new product and therapy we develop. This report shows the evolution of product performance over time and also reveals advances in therapies that come with this experience and knowledge. Through this sharing of information we can enable physicians to best leverage state-of-the-art therapy delivery and also understand the performance of our devices to best manage patients.
We have tracked 18,572 patients in our ongoing post-market registry. The registry has enrolled 56,563 Neuromodulation system components. Components include pumps, catheters, neurostimulators, leads, and extensions. Data on other events not directly attributed to product performance are also included to provide additional information that may be important for patient management. Although gastric electrical stimulation also involves neurostimulation, the performance of these systems is not included in this report.
We welcome your suggestions on content, format, and any information you may have regarding the performance of Medtronic products. If you have questions or comments, please contact us through the information provided below.
Thank you for your support.
Todd Weaver, PhD, MPH
Senior Clinical Research Manager, Post-Approval Clinical Surveillance